Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study  

作　　者：Jiani Wang Yuwei Liu Renzhi Zhang Zhenyu Liu Zongbi Yi Xiuwen Guan Xinming Zhao Jingying Jiang Jie Tian Fei Ma 

机构地区：[1]Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]Key Laboratory of Molecular Imaging,Beijing Key Laboratory of Molecular Imaging,Institute of Automation,Chinese Academy of Sciences,Beijing 100190,China [3]School of Engineering Medicine,Beihang University,Beijing 100191,China [4]Department of Diagnostic Radiology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [5]School of Artificial Intelligence,University of Chinese Academy of Sciences,Beijing 100080,China

出　　处：《Chinese Medical Journal》2023年第7期863-865,共3页中华医学杂志（英文版）

基　　金：National Key Research and Development Program of China(2021YFF1201300 and 2021YFF1201003);the National Natural Science Foundation of China(Nos.81971662 and 92059103);the Natural Science Foundation of Beijing City(7202105);the Key Project of Beijing Hope Marathon Special Fund from the China Cancer Foundation(LC2018A20)

摘　　要：To the Editor:Oncology precision medicine aims to identify patientsmostlikely torespondeffectivelytotherapies.Efforts to establish a survival prediction model using a single platform have not yet met the precision medicine goals.

关 键 词：BREAST HER2 PROSPECTIVE 

分 类 号：R737.9[医药卫生—肿瘤]